Globus Medical’s board of directors authorized a share repurchase program of up to $500 million of the company’s outstanding common stock. Timing and number of repurchased shares will be determined by ...

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors ...

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response ...

Globus Medical stock is down today on an unexpectedly soft Q1 amid an earlier-than-planned integration with recently acquired ...

BTIG analyst Ryan Zimmerman lowered the firm’s price target on Globus Medical (GMED) to $77 from $88 and keeps a Buy rating on the shares. The ...

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025.

Discover key Q1 2025 insights from Globus Medical, including revenue trends, the Nevro acquisition, free cash flow growth, and future strategies.

Globus Medical, Inc.’s GMED share price has dipped by 21.03%, which has investors questioning if this is right time to buy.

Globus Medical expects full-year earnings in the range of $3 to $3.30 per share, with revenue in the range of $2.8 billion to $2.9 billion. This story was generated by Automated Insights ( ...